Dr. Stelios Florinas

Senior Medical Science Liaison Indication: metastatic uveal melanoma, cutaneous melanoma Region: Germany

Inflammation and Immunology Department with focus on Psoriasis and Psoriasis Arthritis

• Developed targeted nanomedicines for the treatment of cancer • Initialized internal and external collaborations that lead to two scientific publications in high impact factor journals • Manage and oversee Medimmune postdoctoral association budget, compile annual program report and organize annual postdoc retreat

• Awarded the Japan-Society-for-the-Promotion-of-Science (JSPS) Fellowship • Managed international research project between Medimmune and U-Tokyo • Synthesized, characterized and evaluated new targeted cancer nanomedicines in a small animal model

• Nonviral siRNA delivery using polymeric vectors, microbubbles and physical methods such as ultrasound • Small animal xenograft tumor model for gene delivery evaluation, biodistribution analysis via FMT imaging

• Project I: Consulted Prof. Scott Anderson, the Department of Chemistry, University of Utah, on commercializing their homogenous media ball milling procedure for soft metal nanoparticles • Project II: Conducted market research for Blackrock Microsystems and their microarray technology for EEG and EMG monitoring to move from the use in humans into small animal research

• Worked as a full-time pharmacist in a geriatric medicine specialized pharmacy • Trained pharmaceutical technicians • Responsible for the documentation of narcotic substances

Developed new strategies for tumor targeting and siRNA delivery.

Master’s-thesis: “Advantages of bioreducible polycation poly(TETA/CBA) and the comparison to non-bioreducible polycation poly(TETA/HMBA)”

Approbierter Apotheker